TMDX

TransMedics Group, Inc.

Healthcare
Medical - Devices
$2.84B market cap

Forecast run · Sep 14, 2026Upside rank 782 of 3,136

Model Signal

ForecastQ Daily Probabilities

49.3%

27.1%

27.7%

Analyst Consensus

Recommendation2.31/5 Buy

Last price$82.18

Price target$96.86

Implied move+17.9%

Analysts13

ForecastQ Portfolios

TMDX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.